
Life sciences job openings · Updated 2026-07-13
Capricor Therapeutics to Report Second Quarter 2026 Financial Results and Provide Recent Corporate Update on August 13
Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel
The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy
Capricor Comments on Briefing Materials Ahead of July 29 FDA Advisory Committee Meeting for Deramiocel
Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference
From official company newsrooms and press releases.
Company description, mission, culture, and benefits — visible after this page is claimed and verified.
Sign up free to search all 6 openings with AI-powered matching.
Search Capricor Therapeutics JobsProfile generated from publicly available hiring data.
·Are you Capricor Therapeutics? Claim this page or contact us